OpenADMET-ExpansionRx: ADMET Data from RNA-Targeted Drug Discovery Campaigns

Real-world ADMET data collected during drug discovery campaigns by Expansion Therapeutics targeting RNA-mediated diseases, finalized in January 2026. The dataset was used in the OpenADMET-ExpansionRx blind challenge and is now released in full. It contains measurements likely related to the absorption, distribution, metabolism, excretion, and toxicity of candidate molecules.

Use Cases

• Train ADMET property prediction models based on molecular features from drug discovery campaigns.
• Benchmark machine learning algorithms for molecular property prediction using the challenge's blind test framework.
• Analyze relationships between molecular structure and pharmacokinetic profiles based on real-world campaign data.
• Study optimization patterns for drug candidates targeting RNA-mediated diseases.

Strengths

• Data originates from real, recently prosecuted drug discovery campaigns by a named company, Expansion Therapeutics.
• Dataset was used in a structured blind challenge, suggesting a defined evaluation context.
• Full dataset release includes previously blinded test data, providing a complete view.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count and file size are unknown, which may limit suitability assessment.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Expansion Therapeutics drug discovery campaigns.

Collection Method

Collected during the optimization of candidate molecules for preclinical programs targeting RNA-mediated diseases.

Time Range

Data finalized for challenge in January 2026.

Freshness

Last updated 2026-01-27 03:10:43; freshness should be verified.